Predicting GLP-1 Discontinuation From Pharmacy Claims
Published: | Updated:
|Articles|September 1, 1997
Supplements and Featured Publications
- Cost-Effective Treatment of Rhinitis: A Managed Care Perspective
- Volume 3
- Issue 9 Suppl
Assessing Outcomes Parameters
Advertisement
Articles in this issue
about 29 years ago
Goals and Objectivesabout 29 years ago
The Health and Economic Impact of Rhinitisabout 29 years ago
Issues in Diagnosing and Therapyabout 29 years ago
Selected Abstractsabout 29 years ago
CME Quizabout 29 years ago
Bibliographyabout 29 years ago
Participantsabout 29 years ago
Introduction: Rhinitis - What It Means and Why It MattersAdvertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Tozorakimab Cuts COPD Exacerbations Up to 34% in Phase 3 Trials
2
Trump Admin Awards $106M to Expand Rural Health Care in NY, RI, MI
3
FDA Approves First Disease-Modifying Treatment for AxD
4
Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show
5